Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
TOKYO, Mar 13 (Pulse News Wire) – HISAMITSU PHARMACEUTICAL CO.,INC. (4530.T) announced that its board has expressed support for the management buyout by the bidder at ¥5,280 per share. The board reco
View all HISAMITSU PHARMACEUTICAL CO.,INC. disclosures →
TOKYO, Mar 13 (Pulse News Wire) – HISAMITSU PHARMACEUTICAL CO.,INC. (4530.T) announced that its board has expressed support for the management buyout by the bidder at ¥5,280 per share.
The board recommends that shareholders tender their shares.
The company established an independent special committee to review the transaction.
🟢 Confidence: High AI-translated content.